博纳吐单抗治疗急性淋巴细胞白血病结局相关生物标志物
本研究基于一项费城染色体阴性复发/难治B细胞前体急性淋巴细胞白血病成人3期研究,随机2:1接受博纳吐单抗或化疗,用基线血样寻找预后或预测生物标志物。基线血小板、肿瘤负荷和T细胞比例为预后标志物,CD45+CD3+CD8+T细胞比例较高与博纳吐单抗后血液学缓解相关,未发现与≥3级不良事件风险相关的标志物。
要点
- 基线血小板每增加1个对数与6个月生存改善相关
- 较低肿瘤负荷与血液学缓解相关,较高CD3+T细胞比例与MRD缓解相关
- CD45+CD3+CD8+T细胞比例较高与博纳吐单抗后血液学缓解相关
核心结论
- 基线血小板、肿瘤负荷和T细胞比例是预后生物标志物。
- 较高CD45+CD3+CD8+T细胞比例与博纳吐单抗后血液学缓解相关。
- 未发现与≥3级不良事件风险显著相关的受检生物标志物。
研究设计与样本
- 3期研究的事后生物标志物分析,患者为费城染色体阴性复发/难治B细胞前体急性淋巴细胞白血病成人。
- 患者按2:1随机接受博纳吐单抗或化疗,博纳吐单抗每6周给药4周。
- 博纳吐单抗剂量为第1周期第1周9 μg/日,之后28 μg/日。
主要发现
- 基线血小板每增加1个对数,与6个月生存改善相关(预后性)。
- 较低肿瘤负荷与血液学缓解相关(预后性)。
- 较高CD3+T细胞比例与MRD缓解相关(预后性)。
- 较高CD45+CD3+CD8+T细胞比例与博纳吐单抗后血液学缓解相关。
临床怎么用
- 可考虑将基线血小板、肿瘤负荷和T细胞比例纳入预后评估。
- CD45+CD3+CD8+T细胞比例或有助于识别博纳吐单抗获益人群。
局限性
- 为3期研究的生物标志物分析,结论需未来研究验证。
- 摘要未报告样本量、效应值、置信区间和P值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study aimed to identify biomarkers for clinical outcomes in a phase 3 clinical study of blinatumomab or chemotherapy in adults with Philadelphia chromosome-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Patients were randomized 2:1 to receive blinatumomab, a BiTE® therapy, for 4 weeks (9 μg/day cycle 1 week 1, 28 μg/day thereafter) every 6 weeks, or chemotherapy. Baseline blood samples were evaluated to identify biomarkers prognostic (both treatment groups) or predictive (either treatment groups) for overall survival, event-free survival, hematologic remission, minimal residual disease (MRD) response, duration of response, or adverse events. Baseline values were balanced between treatment groups. Prognostic biomarkers were platelets, tumor burden, and percentage of T cells: each 1-log increase in platelets at baseline was prognostic for improved 6-month survival; lower tumor burden was prognostic for hematologic remission; and a higher percentage of CD3+ T-cells was prognostic for MRD response. Consistent with the BiTE mechanism of action, higher percentage of CD45+ CD3+ CD8+ T cells was associated with hematologic remission following blinatumomab. No examined biomarkers were significant for the risk of grade ≥3 adverse events. Incorporating baseline biomarkers into future studies may help to identify subgroups most likely to benefit from blinatumomab.
引用
- Wei AH, Ribera JM, Larson RA, et al. Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. Leukemia. 2021. PMID: 33542479. doi:10.1038/s41375-020-01089-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。